Introduction
============

Esophagogastrostomy is associated with high complication and mortality rates \[[@ref1],[@ref2]\]. Anastomotic leaks are among the most significant complications following this surgical procedure, with incidence rates reported to range from 6.2% and 27% \[[@ref3][@ref4]-[@ref5]\]. Further, leak-associated mortality rates range from 18% to 40%, compared to overall in-hospital mortality rates of 4%--6% \[[@ref6]\].

One of the main causes of anastomotic leaks is poor perfusion of anastomotic sites during reconstruction following esophagectomy \[[@ref7]\]. The anastomosis area is often weak because the gastroepiploic arterial supply rarely reaches the end of the graft. This may cause various complications such as tissue necrosis, edema, and subsequent anastomotic leakage \[[@ref8][@ref9][@ref10]-[@ref11]\]. Until recently, ischemia of the anastomosis area was accepted as inevitable in some patients. Therefore, predicting the risk of anastomotic leakage by determining the perfusion and viability of the gastric conduit is key to the success of the procedure. However, it is known that judgments made by operating clinicians tend to be relatively non-sensitive and non-specific \[[@ref8],[@ref12],[@ref13]\].

Several technologies are used to evaluate perfusion of the gastric conduit, such as single-photon emission computed tomography (SPECT), computed tomography (CT) angiography, and visible light spectroscopy \[[@ref14]\]. However, SPECT and CT angiography are not available intraoperatively, and visible light spectroscopy provides a limited viewing area \[[@ref15]\]. Alternatively, laser Doppler flowmetry has been used because of its ease of use and time efficiency \[[@ref8],[@ref16]\]. However, it is limited to the microvasculature, and the region of interest is small \[[@ref17]\].

Recently, indocyanine green (ICG) fluorescence imaging has been adopted for intraoperative assessment of the blood supply to various reconstructed organs \[[@ref17]\]. Several studies have evaluated similar methods of intraoperative imaging of perfusion of the colon, muscle flaps, and even the gastric conduit \[[@ref18]\]. Zehetner et al. \[[@ref19]\] assessed gastric conduit perfusion in 150 patients who underwent esophagectomy using this technology and found that perfusion at the site of anastomosis was significantly associated with the presence of an anastomotic leak. Newer fluorescence imaging systems can provide a superimposed fluorescence image on top of the color image to make recognition more intuitive. Therefore, image-based, real-time evaluation of perfusion can reliably predict desirable clinical outcomes.

Since the first study of ICG fluorescence imaging for the evaluation of gastric conduit perfusion was conducted in 2011 \[[@ref17]\], surgeons have tried to bring this technology into clinical practice. However, there are insufficient data on the dosage of ICG and how to interpret the fluorescence images.

Dosage of indocyanine green
===========================

ICG has been used to evaluate hepatic function and outline hepatectomy strategies for oncologic resections for more than 30 years, and 0.5 mg/kg of ICG is a routine dose for these measurements \[[@ref20]\]. Up to 2 mg/kg is considered to be a safe dose, and 5 mg/kg is the maximum intravenous dose for humans \[[@ref21]\].

In a previous study, we showed that 0.6 mg/kg of ICG was an optimal dose to define the intersegmental plane based on blood perfusion during lung segmentectomy \[[@ref22]\]. The same dose of ICG enabled successful detection of a fluorescence signal from the gastric tube in a preclinical study with pigs \[[@ref14]\]. This dose is similar to the original dose used to evaluate hepatic function before hepatic segmentectomy and is hence familiar and easily adopted by surgeons.

ICG solution is made by dissolving 25 mg of ICG in powder form into 10 mL of distilled water just before usage, resulting in a concentration of 2.5 mg/mL. In real- world clinical situations, injection of a certain mass (in milligrams) of the solution is easier than calculating each dose of ICG according to the patient's body weight. Therefore, most studies have suggested using a certain amount of ICG solution for evaluating gastric tube perfusion, with a range of 1.25--36 mg \[[@ref14],[@ref17],[@ref23][@ref24][@ref25][@ref26][@ref27][@ref28][@ref29][@ref30][@ref31][@ref32][@ref33][@ref34][@ref35][@ref36][@ref37][@ref38][@ref39][@ref40][@ref41][@ref42][@ref43]-[@ref44]\] ([Table 1](#T1){ref-type="table"}). Recent studies have suggested that 7.5--12.5 mg is the optimal dose for ICG fluorescence image-based evaluation of gastric tube perfusion. Based on our experience, 7.5 mg (3 mL) of ICG when using the Pinpoint Thoracoscope (Novadaq Technologies Inc., Mississauga, ON, Canada) and 12.5 mg (5 mL) when using the Firefly fluorescence imaging system (da Vinci Si system; Intuitive Surgical Inc., Sunnyvale, CA, USA) are recommended because each near-infrared fluorescence imaging system has a different fluorescence intensity.

Interpretation of indocyanine green fluorescence images for the measurement of gastric conduit perfusion
========================================================================================================

Zehetner et al. \[[@ref19]\] reported that a leak was signiﬁcantly less likely when the anastomosis was placed in an area of good perfusion than when it was placed in an area of less robust perfusion using ICG fluorescence imaging (2% versus 45%) in 144 patients who underwent esophagogastric anastomosis. They suggested that altering the surgical plan is necessary for some patients who show poor perfusion in the gastric tube on fluorescence images during esophagectomy with esophagogastrostomy to reduce anastomotic morbidity and promote better overall patient outcomes.

Murawa et al. \[[@ref45]\] attempted to change the anastomotic site of the gastric tube based on perfusion status under real-time fluorescence imaging. Insufficient blood perfusion was shown in 4 of 15 patients on fluorescence images. In these 4 patients, the anastomotic site was switched to an area with good perfusion instead of the originally planned area. This surgical strategy showed better results, and an anastomotic leak was observed only in 1 patient (6.7%). However, there was still an anastomotic leak despite good perfusion at the anastomosis under intraoperative fluorescence imaging guidance.

Kumagai et al. \[[@ref32]\] also presented 2 cases of gastric tube necrosis among 36 cases despite selecting an area with good perfusion in the gastric tube based on fluorescence images. They did not consider the time taken until enhancement of the gastric tube tip when determining the site for esophagogastrostomy. However, a retrospective evaluation of the recorded video for these 2 cases revealed that gastric tube necrosis occurred in areas where more than 90 s was needed for ICG enhancement. Specifically, these 2 cases of gastric tube necrosis required 138 and 103 seconds for the gastric tube tip to become enhanced. Furthermore, when the enhancement time exceeded 60 seconds at the anastomosis site, minor anastomotic leaks developed in some cases. They hypothesized that the risk of anastomotic leakage might be minimized if anastomoses are created in areas that are enhanced within 60 seconds.

Our previous preclinical study also reported that 90 seconds was the optimal time for evaluating gastric tube perfusion status \[[@ref14]\]. The clinical cases in our hospital showed that fluorescence could be completely visualized by approximately 60 seconds in normal gastric tubes ([Fig. 1](#F1){ref-type="fig"}, [Supplementary Video 1](#S1){ref-type="supplementary-material"}). In our hospital, if a non-perfused area is observed in the gastric tube on fluorescence imaging 60 seconds after ICG injection, another area with good perfusion is selected as the anastomotic site instead of the original site ([Fig. 2](#F2){ref-type="fig"}, [Supplementary Video 2](#S2){ref-type="supplementary-material"}).

Conclusion
==========

A fluorescence imaging system allows visualization over a wide region of interest and provides intuitive information on perfusion from the gastric tube during esophagectomy and esophagogastrostomy. Surgeons can determine, in real time, the best anastomotic site of the gastric tube based on intraoperative fluorescence images. This technology is associated with better surgical outcomes when used with an optimal injection dose and timing of ICG.

Supplemental Materials
======================

Supplementary materials can be found via <https://doi.org/10.5090/kjtcs.2020.53.4.178>. **[Supplementary Video 1](#S1){ref-type="supplementary-material"}**. The clinical cases in our hospital showed that fluorescence could be completely visualized by approximately 60 seconds in normal gastric tubes. **[Supplementary Video 2](#S2){ref-type="supplementary-material"}**. Fluorescence images showing a non-perfused area of the gastric tube 60 seconds after the injection of indocyanine green.
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![(A--C) Intraoperative evaluation of gastric tube perfusion on indocyanine green fluorescence images over time.](KJTCV-53-178-f1){#F1}

![(A--C) Fluorescence images showing a non-perfused area of the gastric tube 60 seconds after the injection of indocyanine green. The arrow shows the border line between the perfused and non-perfused area of the gastric tube.](KJTCV-53-178-f2){#F2}
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Dosage of indocyanine green for intraoperative evaluation of the gastric tube

  Dose      Year   Authors              Journals                         References
  --------- ------ -------------------- -------------------------------- --------------
  1.25 mg   2016   Koyanagi et al.      Medicine (Baltimore)             \[[@ref23]\]
            2019   Ishige et al.        J Surg Res                       \[[@ref24]\]
  2.5 mg    2011   Shimada et al.       Esophagus                        \[[@ref17]\]
            2012   Ishiguro et al.      Int Surg                         \[[@ref25]\]
            2014   Kumagai et al.       World J Surg                     \[[@ref26]\]
            2014   Rino et al.          BMC Med Imaging                  \[[@ref27]\]
            2014   Zehetner et al.      Ann Surg                         \[[@ref28]\]
            2015   Fikfak et al.        Int J Surg Case Rep              \[[@ref29]\]
            2016   Hachey et al.        J Thorac Cardiovasc Surg         \[[@ref30]\]
            2016   Kazuo et al.         Medicine (Baltimore)             \[[@ref23]\]
            2017   Masaki et al.        Esophagus                        \[[@ref31]\]
            2018   Koyanagi et al.      Dis Esophagus                    \[[@ref32]\]
            2018   Nishikawa et al.     Ann Surg                         \[[@ref33]\]
  5 mg      2015   Campbell et al.      J Gastrointest Surg              \[[@ref34]\]
            2015   Kitagawa et al.      Anticancer Res                   \[[@ref35]\]
            2015   Kamiya et al.        J Surg Res                       \[[@ref36]\]
            2017   Schlottmann et al.   J Laparoendosc Adv Surg Tech A   \[[@ref37]\]
  7.5 mg    2016   DeLong et al.        J Vis Surg                       \[[@ref38]\]
            2017   Karampinis et al.    Int J Surg                       \[[@ref39]\]
  12.5 mg   2018   Noma et al.          J Am Coll Surg                   \[[@ref40]\]
            2019   Sugimura et al.      J Surg Res                       \[[@ref41]\]
  25 mg     2012   Saito et al.         J Surg Oncol                     \[[@ref42]\]
            2018   Miyauchi et al.      Yonago Acta Med                  \[[@ref43]\]
  30 mg     2018   Van Daele et al.     Medicine (Baltimore)             \[[@ref44]\]
  36 mg     2018   Quan et al.          J Thorac Dis                     \[[@ref14]\]

[^1]: This article was presented at the 6th Esophageal Cancer Symposium (lecture on No­vember 16th, 2019, Samsung Medical Center, Seoul, Korea).
